GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cipla Ltd (NSE:CIPLA) » Definitions » Inventories, Finished Goods

Cipla (NSE:CIPLA) Inventories, Finished Goods : ₹0 Mil (As of Dec. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Cipla Inventories, Finished Goods?

Cipla's annual finished goods increased from Mar. 2022 (₹25,600 Mil) to Mar. 2023 (₹26,440 Mil) but then declined from Mar. 2023 (₹26,440 Mil) to Mar. 2024 (₹26,287 Mil).


Cipla Inventories, Finished Goods Historical Data

The historical data trend for Cipla's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cipla Inventories, Finished Goods Chart

Cipla Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16,713.90 18,404.20 25,599.50 26,440.40 26,287.30

Cipla Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 26,287.30 - - -

Cipla Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Cipla Business Description

Industry
Traded in Other Exchanges
Address
Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.

Cipla Headlines

No Headlines